RATPAC Research Team members are listed in †.
1553-2712/asset/olbannerleft.jpg?v=1&s=9d7975279d4b267cf24fb3ccf4a4682cc75d4712)
You have full text access to this OnlineOpen article
Cost-effectiveness of Point-of-care Biomarker Assessment for Suspected Myocardial Infarction: The Randomized Assessment of Treatment Using Panel Assay of Cardiac Markers (RATPAC) Trial
Article first published online: 13 MAY 2011
DOI: 10.1111/j.1553-2712.2011.01068.x
© 2011 by the Society for Academic Emergency Medicine
Additional Information
How to Cite
Fitzgerald, P., Goodacre, S. W., Cross, E. and Dixon, S. (2011), Cost-effectiveness of Point-of-care Biomarker Assessment for Suspected Myocardial Infarction: The Randomized Assessment of Treatment Using Panel Assay of Cardiac Markers (RATPAC) Trial. Academic Emergency Medicine, 18: 488–495. doi: 10.1111/j.1553-2712.2011.01068.x
The RATPAC trial was funded by the National Institute for Health Research (NIHR) Health Technology Assessment (HTA) Program (06/302/19). The study funders had no role in study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication. The researchers were independent of the study funders. The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the NIHR HTA. All authors have completed the Unified Competing Interest form at http://www.icmje.org/coi_disclosure.pdf and declare that they have no conflicts of interest to declare.
Supervising Editor: Richard Byyny, MD, MSc.
Publication History
- Issue published online: 13 MAY 2011
- Article first published online: 13 MAY 2011
- Received August 3, 2010; revisions received October 21 and November 21, 2010; accepted November 21, 2010.
References
- 1, , , , , . The health care burden of acute chest pain. Heart. 2005; 91:229–30.
- 2
- 3, , , , , , on behalf of the RATPAC research team. The RATPAC Trial (Randomised Assessment of Treatment using Panel Assay of Cardiac markers): a randomised controlled trial of point-of-care cardiac markers in the emergency department. Heart. 2011; 97:190–6.
- 4National Institute for Health and Clinical Excellence. Guidance for the Management of Acute Chest Pain. Available at: http://guidance.nice.org.uk/CG95. Accessed Mar 4, 2011.
- 5, , , et al. Good research practices for cost-effectiveness analysis alongside clinical trials: The ISPOR RCT-CEA Task Force Report. Value Health. 2005; 8:521–33.
- 6National Institute for Clinical Excellence. Guide to the Methods of Technology Appraisal. London, UK: NICE, April 2004.
- 7, , , et al. Randomised controlled trial and economic evaluation of a chest pain observation unit compared with routine care. BMJ. 2004; 328:254–7.
- 8, Unit Costs of Health and Social Care 2004. University of Kent, Personal Social Services Research Unit. Available at: http://www.pssru.ac.uk/uc/uc2004.htm. Accessed Mar 4, 2011.
- 9The National Archives. NHS Reference Costs 2004–2005. Available at: http://webarchive.nationalarchives.gov.uk/+/www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_4133221. Accessed Mar 4, 2011.
- 10, , . Representing uncertainty: the role of cost effectiveness acceptability curves. Health Econ Let. 2001; 10:779–87.
- 11. Permutation, Parametric and Bootstrap Tests of Hypothesis, 3rd ed. New York, NY: Springer, 2005.
- 12
- 13, . Is a chest pain observation unit likely to be cost-effective at my hospital? Extrapolation of data from a randomised controlled trial. Emerg Med J. 2005; 418–22.